Replies to post #177343 on Innovation Pharmaceuticals Inc (IPIX)

[baytdr]

"OC phase 2A could yield some good outcomes"
If positive, this 2A will at the very least inform the design of the next trial and encourage physicians and patients to favorably consider participation in a double blind trial, which is a leap of faith due to the placebo arm, which will be required by the FDA.

[To infinity and beyond!]

They were pursuing a real survival study. Now they are going back to safety and moa. What is there to agree or disagree about? The company announces that the baby is going to walk, and then they realize it is not ready? They issue PR after PR over many months about the baby walking and then- sorry, back to a crawl.
Because they failed to demonstrate safety at more frequent doing? Or because they have no money for a real trial?

OC will yield more info but not the info the company needs to move forward with other cancers other trials, renal pancreatic etc

you know- the stuff they used to say was moving forward.

The real info needed- survival data- will now be on hold for another year- 2017 now mostly a loss for K

Of course they will learn more about it, but...

Am I surprised? Of course not- you will recall my constant whining about not establishing safety at more frequent dosing. But why should I have been the one totell you this, and see it come to pass, and not CTIX? Menon shoulda been telling us this- we need more data- a long time ago, instead of announcing, in agonizing detail their progress on the ovarian trial)final trial plans were put in the mail to the FDA yadda yadda PR kinda stuff, we are moving forward with clinical trial rather than the current course

hey guess what shareholders, all along we knew they needed MORE data . They shoulda said so a long time back.